Science
-
Research updates, August 25
Another observational study found more evidence of endothelial dysfunction in Long COVID. German researchers evaluated the eyes of 102 people with Long COVID, comparing them to 102 people “recovered” from COVID-19, as well as controls.
-
Research updates, August 18
Researchers found immune abnormalities in the intestines of people with Long COVID, according to a new preprint. The small study compared colon tissue samples and blood of 44 people with Long COVID to 13 controls who “recovered” from COVID-19, using several different analysis methods.
-
VIPER aims to fast track Long COVID biomarkers. Here’s how it works.
Led by researchers at UCSF, the research program plans to validate promising candidates for noninvasive tests that can be used to advance clinical trials.
-
Research updates, August 11
COVID-19 can reactivate dormant viruses in the body, confirms new research in Nature.
-
Research updates, August 4
A new study in Nature Communications confirmed skeletal muscle abnormalities in Long COVID and ME. The study, which furthered past research on post-exertional malaise from the same research group, compared various exercise tests and biopsies of people with Long COVID and ME to results from people who underwent 60 days of strict bedrest, as well…
-
Dysautonomia conference centers biomarkers and post-exertional malaise
The 14th annual Dysautonomia International conference outside Houston included presentations on the role of autoimmunity in dysautonomia and a biobank initiative for POTS research.
-
Research updates, July 28
A new study found persistent neuromuscular abnormalities in Long COVID. The small follow-up study, published in Neurophysiologie Clinique, included 50 people with Long COVID who underwent two types of electromyography tests, which can provide objective measures of muscle function.
-
How to interpret clinical trial results for Long COVID
With no proven treatments or cures, many people with Long COVID are turning to off-label medications, supplements, and medical devices to treat their symptoms. There are numerous options — and some of them even have clinical trials underway or are reporting results. But even if one study suggests a treatment might work, another might contradict…
-
Research updates, July 21
The dementia drug donepezil helped decrease fatigue in a subset of people with Long COVID, according to a study published in Frontiers in Pharmacology. In the complex study, which also included testing in mice, Japanese researchers found a majority of people with Long COVID in the cohort had reactivated human herpes virus 6 (HHV-6), which produced…
-
Experimental peptides are being advertised for Long COVID. But the evidence is trailing behind.
Some FDA-approved GLP-1s are being studied in clinical trials for the disease, but their results aren’t available yet. Experts caution against using experimental peptides for Long COVID.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
-
Trans people with Long COVID navigate a new “dark age” in trans health
-
National COVID-19 trends, October 13
-
Research updates, October 13
-
How I built a COVID-safer school that’s become the heart of a more caring community
-
Biological pathways and mechanistic trials centered at new Long COVID conference in Amsterdam
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance